A committee of European Medicines Agency advisers is recommending approval for Novo Nordisk's combination of a long-acting insulin and its blockbuster GLP-1 drug Victoza, setting the stage for a near-term approval of what's expected to be the diabetes giant's next big therapy.
The pharma sector in India is reeling after the National Pharmaceutical Pricing Authority said it's capping prices on about 100 drugs to treat diabetes and heart disease. And the company that could suffer most isn't India-based.
A chemical compound designed by researchers at the University of California, San Francisco, protected mice and rats against degenerative forms of blindness and diabetes by targeting a central stress response area.
Across three Phase III trials, Sanofi's in-development replacement for Lantus was better at battling low blood sugar than the company's cash cow insulin product, providing hope for the drugmaker's diabetes business when its blockbuster goes off patent next year.
Sanofi has formed an alliance with medical device titan Medtronic to develop combo therapies that can improve patient adherence and simplify insulin treatment for the world's roughly 350 million sufferers of Type 2 diabetes.
Combine the blockbuster GLP-1 drug Victoza with a long-acting insulin and you get a treatment greater than the sum of its parts, according to Novo Nordisk, which unveiled promising new data on its diabetes cocktail IDegLira.
Eli Lilly will hardly be the first in the field of GLP-1 treatments for diabetes if and when it launches dulaglutide, but the company believes its drug has the data to stand out among its rivals and claim the lion's share of a multibillion-dollar market.
French diagnostics outfit Sebia is up for sale, and its current private equity owner hopes to fetch a cool $1.37 billion for it.
Following in the footsteps of companies that have enlisted celebrities as diabetes spokespeople, the New Jersey-based pharma has recruited actress S. Epatha Merkerson to help it talk to patients about blood sugar control.
KineMed, a California biomarker test developer with IPO plans, is joining a consortium that will create a standard mouse model focused on diagnosis and tracking of early-onset diabetes.